Middleton, Mark R.

Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma

Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., et al. (2017) · New England Journal of Medicine

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 2,246

Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial

Ascierto, P. A., Del Vecchio, M., Mandalá, M., Gogas, H., Arance, A. M., Dalle, S., Cowey, C. L., Schenker, M., Grob, J.-J., Chiarion-Sileni, V., et al. (2020) · The Lancet Oncology

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 537

Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RAS–RAF Mutations

Zimmer, L., Barlesi, F., Martinez-Garcia, M., Dieras, V., Schellens, J. H. M., Spano, J.-P., Middleton, M. R., Calvo, E., Paz-Ares, L., Larkin, J., et al. (2014) · Clinical Cancer Research

Melanoma and MAPK PathwaysProtein Tyrosine Phosphatases

Cited by 71

Tumour gene expression signature in primary melanoma predicts long-term outcomes

Garg, M., Couturier, D.-L., Nsengimana, J., Fonseca, N. A., Wongchenko, M., Yan, Y., Lauss, M., Jönsson, G. B., Newton-Bishop, J., Parkinson, C., et al. (2021) · Nature Communications

Cutaneous Melanoma Detection and ManagementBreast Cancer Treatment Studies

Cited by 70

Combination Therapies for the Optimisation of Bispecific T-Cell Engagers in Cancer Treatment

Zhu, W. M., & Middleton, M. R. (2023) · Immunotherapy Advances

Cancer Immunotherapy and BiomarkersMonoclonal and Polyclonal Antibodies Research

Cited by 46